-
1
-
-
79959503595
-
Peripheral T-cell lymphoma
-
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST and Tobinai K. Peripheral T-cell lymphoma. Blood. 2011; 117:6756-6767.
-
(2011)
Blood
, vol.117
, pp. 6756-6767
-
-
Foss, F.M.1
Zinzani, P.L.2
Vose, J.M.3
Gascoyne, R.D.4
Rosen, S.T.5
Tobinai, K.6
-
2
-
-
84899631361
-
Antibodymodified T cells: CARs take the front seat for hematologic malignancies
-
Maus MV, Grupp SA, Porter DL and June CH. Antibodymodified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014; 123:2625-2635.
-
(2014)
Blood
, vol.123
, pp. 2625-2635
-
-
Maus, M.V.1
Grupp, S.A.2
Porter, D.L.3
June, C.H.4
-
4
-
-
84959357452
-
Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
-
Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW, Hagag N, Schuster M, Firor AE, Jiang X and Ma Y. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia. 2016; 30:701-707.
-
(2016)
Leukemia
, vol.30
, pp. 701-707
-
-
Pinz, K.1
Liu, H.2
Golightly, M.3
Jares, A.4
Lan, F.5
Zieve, G.W.6
Hagag, N.7
Schuster, M.8
Firor, A.E.9
Jiang, X.10
Ma, Y.11
-
5
-
-
77956925717
-
WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview
-
Sabattini E, Bacci F, Sagramoso C and Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010; 102:83-87.
-
(2010)
Pathologica
, vol.102
, pp. 83-87
-
-
Sabattini, E.1
Bacci, F.2
Sagramoso, C.3
Pileri, S.A.4
-
6
-
-
10744233830
-
Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells
-
Rapoport AP, Levine BL, Badros A, Meisenberg B, Ruehle K, Nandi A, Rollins S, Natt S, Ratterree B, Westphal S, Mann D and June CH. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone marrow transplantation. 2004; 33:53-60.
-
(2004)
Bone marrow transplantation
, vol.33
, pp. 53-60
-
-
Rapoport, A.P.1
Levine, B.L.2
Badros, A.3
Meisenberg, B.4
Ruehle, K.5
Nandi, A.6
Rollins, S.7
Natt, S.8
Ratterree, B.9
Westphal, S.10
Mann, D.11
June, C.H.12
-
7
-
-
84926457446
-
Advantages and applications of CAR-expressing natural killer cells
-
Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L and Koehl U. Advantages and applications of CAR-expressing natural killer cells. Frontiers in pharmacology. 2015; 6:21.
-
(2015)
Frontiers in pharmacology
, vol.6
, pp. 21
-
-
Glienke, W.1
Esser, R.2
Priesner, C.3
Suerth, J.D.4
Schambach, A.5
Wels, W.S.6
Grez, M.7
Kloess, S.8
Arseniev, L.9
Koehl, U.10
-
8
-
-
77954590000
-
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their antilymphoma/leukemia effects and safety
-
Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK and Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their antilymphoma/leukemia effects and safety. Leukemia. 2010; 24:1160-1170.
-
(2010)
Leukemia
, vol.24
, pp. 1160-1170
-
-
Hoyos, V.1
Savoldo, B.2
Quintarelli, C.3
Mahendravada, A.4
Zhang, M.5
Vera, J.6
Heslop, H.E.7
Rooney, C.M.8
Brenner, M.K.9
Dotti, G.10
-
9
-
-
84939529597
-
From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy
-
Firor AE, Jares A and Ma Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Experimental biology and medicine. 2015; 240:1087-1098.
-
(2015)
Experimental biology and medicine
, vol.240
, pp. 1087-1098
-
-
Firor, A.E.1
Jares, A.2
Ma, Y.3
-
10
-
-
85015639659
-
Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies
-
Wu C, Hong SG, Winkler T, Spencer DM, Jares A, Ichwan B, Nicolae A, Guo V, Larochelle A and Dunbar CE. Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies. Molecular therapy Methods & clinical development. 2014; 1:14053.
-
(2014)
Molecular therapy Methods & clinical development
, vol.1
, pp. 14053
-
-
Wu, C.1
Hong, S.G.2
Winkler, T.3
Spencer, D.M.4
Jares, A.5
Ichwan, B.6
Nicolae, A.7
Guo, V.8
Larochelle, A.9
Dunbar, C.E.10
-
11
-
-
84946780179
-
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
-
Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG and Tonn T. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy. Cancer immunology, immunotherapy. 2016; 65:485-492.
-
(2016)
Cancer immunology, immunotherapy
, vol.65
, pp. 485-492
-
-
Suck, G.1
Odendahl, M.2
Nowakowska, P.3
Seidl, C.4
Wels, W.S.5
Klingemann, H.G.6
Tonn, T.7
-
12
-
-
84922257867
-
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor
-
Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bonig H, Kohl U, Kloess S, Kohler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kuhlcke K, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Molecular therapy. 2015; 23:330-338.
-
(2015)
Molecular therapy
, vol.23
, pp. 330-338
-
-
Schonfeld, K.1
Sahm, C.2
Zhang, C.3
Naundorf, S.4
Brendel, C.5
Odendahl, M.6
Nowakowska, P.7
Bonig, H.8
Kohl, U.9
Kloess, S.10
Kohler, S.11
Holtgreve-Grez, H.12
Jauch, A.13
Schmidt, M.14
Schubert, R.15
Kuhlcke, K.16
-
13
-
-
84887052348
-
Treatment of patients with advanced cancer with the natural killer cell line NK-92
-
Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG and Bug G. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013; 15:1563-1570.
-
(2013)
Cytotherapy
, vol.15
, pp. 1563-1570
-
-
Tonn, T.1
Schwabe, D.2
Klingemann, H.G.3
Becker, S.4
Esser, R.5
Koehl, U.6
Suttorp, M.7
Seifried, E.8
Ottmann, O.G.9
Bug, G.10
-
14
-
-
84968761575
-
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
-
Zhang C, Burger MC, Jennewein L, Genssler S, Schonfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP and Wels WS. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Journal of the National Cancer Institute. 2016; 108.
-
(2016)
Journal of the National Cancer Institute
, pp. 108
-
-
Zhang, C.1
Burger, M.C.2
Jennewein, L.3
Genssler, S.4
Schonfeld, K.5
Zeiner, P.6
Hattingen, E.7
Harter, P.N.8
Mittelbronn, M.9
Tonn, T.10
Steinbach, J.P.11
Wels, W.S.12
-
15
-
-
67549118956
-
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
-
Boissel L, Betancur M, Wels WS, Tuncer H and Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leukemia research. 2009; 33:1255-1259.
-
(2009)
Leukemia research
, vol.33
, pp. 1255-1259
-
-
Boissel, L.1
Betancur, M.2
Wels, W.S.3
Tuncer, H.4
Klingemann, H.5
-
16
-
-
84902582355
-
Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibodydependent cellular cytotoxicity
-
Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS and Klingemann H. Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibodydependent cellular cytotoxicity. Oncoimmunology. 2013; 2:e26527.
-
(2013)
Oncoimmunology
, vol.2
-
-
Boissel, L.1
Betancur-Boissel, M.2
Lu, W.3
Krause, D.S.4
Van Etten, R.A.5
Wels, W.S.6
Klingemann, H.7
-
17
-
-
84898461706
-
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
-
Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC and Yu J. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014; 28:917-927.
-
(2014)
Leukemia
, vol.28
, pp. 917-927
-
-
Chu, J.1
Deng, Y.2
Benson, D.M.3
He, S.4
Hughes, T.5
Zhang, J.6
Peng, Y.7
Mao, H.8
Yi, L.9
Ghoshal, K.10
He, X.11
Devine, S.M.12
Zhang, X.13
Caligiuri, M.A.14
Hofmeister, C.C.15
Yu, J.16
-
18
-
-
84894325649
-
Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
-
Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W, Man-Yuen Sze D, Yi Q and Hou J. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Molecular oncology. 2014; 8:297-310.
-
(2014)
Molecular oncology
, vol.8
, pp. 297-310
-
-
Jiang, H.1
Zhang, W.2
Shang, P.3
Zhang, H.4
Fu, W.5
Ye, F.6
Zeng, T.7
Huang, H.8
Zhang, X.9
Sun, W.10
Man-Yuen Sze, D.11
Yi, Q.12
Hou, J.13
-
19
-
-
33750061330
-
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells
-
Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G and Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 2006; 20:1819-1828.
-
(2006)
Leukemia
, vol.20
, pp. 1819-1828
-
-
Loskog, A.1
Giandomenico, V.2
Rossig, C.3
Pule, M.4
Dotti, G.5
Brenner, M.K.6
-
20
-
-
3042551216
-
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
-
Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL and Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004; 18:676-684.
-
(2004)
Leukemia
, vol.18
, pp. 676-684
-
-
Imai, C.1
Mihara, K.2
Andreansky, M.3
Nicholson, I.C.4
Pui, C.H.5
Geiger, T.L.6
Campana, D.7
-
21
-
-
0026022298
-
Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation
-
Hooks MA, Wade CS and Millikan WJ, Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 1991; 11:26-37.
-
(1991)
Pharmacotherapy
, vol.11
, pp. 26-37
-
-
Hooks, M.A.1
Wade, C.S.2
Millikan, W.J.3
-
22
-
-
64249158870
-
Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma
-
Frankel AE, Zuckero SL, Mankin AA, Grable M, Mitchell K, Lee YJ, Neville DM and Woo JH. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Current drug targets. 2009; 10:104-109.
-
(2009)
Current drug targets
, vol.10
, pp. 104-109
-
-
Frankel, A.E.1
Zuckero, S.L.2
Mankin, A.A.3
Grable, M.4
Mitchell, K.5
Lee, Y.J.6
Neville, D.M.7
Woo, J.H.8
-
23
-
-
35648941736
-
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis
-
Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M and Lowder J. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007; 133:1414-1422.
-
(2007)
Gastroenterology
, vol.133
, pp. 1414-1422
-
-
Plevy, S.1
Salzberg, B.2
Van Assche, G.3
Regueiro, M.4
Hommes, D.5
Sandborn, W.6
Hanauer, S.7
Targan, S.8
Mayer, L.9
Mahadevan, U.10
Frankel, M.11
Lowder, J.12
-
24
-
-
77955280646
-
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes
-
Hale G, Rebello P, Al Bakir I, Bolam E, Wiczling P, Jusko WJ, Vandemeulebroucke E, Keymeulen B, Mathieu C, Ziegler AG, Chatenoud L and Waldmann H. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. Journal of clinical pharmacology. 2010; 50:1238-1248.
-
(2010)
Journal of clinical pharmacology
, vol.50
, pp. 1238-1248
-
-
Hale, G.1
Rebello, P.2
Al Bakir, I.3
Bolam, E.4
Wiczling, P.5
Jusko, W.J.6
Vandemeulebroucke, E.7
Keymeulen, B.8
Mathieu, C.9
Ziegler, A.G.10
Chatenoud, L.11
Waldmann, H.12
-
25
-
-
84902590288
-
Are natural killer cells superior CAR drivers?
-
Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014; 3:e28147.
-
(2014)
Oncoimmunology.
, vol.3
-
-
Klingemann, H.1
-
26
-
-
0032447111
-
Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells
-
Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES and Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. The Journal of experimental medicine. 1998; 188:2375-2380.
-
(1998)
The Journal of experimental medicine
, vol.188
, pp. 2375-2380
-
-
Zamai, L.1
Ahmad, M.2
Bennett, I.M.3
Azzoni, L.4
Alnemri, E.S.5
Perussia, B.6
-
27
-
-
34848842554
-
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts
-
Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintas-Cardama A, Larson SM and Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical cancer research. 2007; 13:5426-5435.
-
(2007)
Clinical cancer research
, vol.13
, pp. 5426-5435
-
-
Brentjens, R.J.1
Santos, E.2
Nikhamin, Y.3
Yeh, R.4
Matsushita, M.5
La Perle, K.6
Quintas-Cardama, A.7
Larson, S.M.8
Sadelain, M.9
-
28
-
-
84882410441
-
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia
-
Barrett DM, Liu X, Jiang S, June CH, Grupp SA and Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Human gene therapy. 2013; 24:717-727.
-
(2013)
Human gene therapy
, vol.24
, pp. 717-727
-
-
Barrett, D.M.1
Liu, X.2
Jiang, S.3
June, C.H.4
Grupp, S.A.5
Zhao, Y.6
-
29
-
-
84940025175
-
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
-
Mamonkin M, Rouce RH, Tashiro H and Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015; 126:983-992.
-
(2015)
Blood
, vol.126
, pp. 983-992
-
-
Mamonkin, M.1
Rouce, R.H.2
Tashiro, H.3
Brenner, M.K.4
-
30
-
-
84902685650
-
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
-
Beldjord K, Chevret S, AsnafiV, Huguet F, Boulland ML, Leguay T, Thomas X, Cayuela JM, Grardel N, Chalandon Y, Boissel N, Schaefer B, Delabesse E, Cave H, Chevallier P, Buzyn A, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014; 123:3739-3749.
-
(2014)
Blood
, vol.123
, pp. 3739-3749
-
-
Beldjord, K.1
Chevret, S.2
Asnafi, V.3
Huguet, F.4
Boulland, M.L.5
Leguay, T.6
Thomas, X.7
Cayuela, J.M.8
Grardel, N.9
Chalandon, Y.10
Boissel, N.11
Schaefer, B.12
Delabesse, E.13
Cave, H.14
Chevallier, P.15
Buzyn, A.16
-
31
-
-
84877087137
-
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma
-
Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT and Kochenderfer JN. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical cancer research. 2013; 19:2048-2060.
-
(2013)
Clinical cancer research
, vol.19
, pp. 2048-2060
-
-
Carpenter, R.O.1
Evbuomwan, M.O.2
Pittaluga, S.3
Rose, J.J.4
Raffeld, M.5
Yang, S.6
Gress, R.E.7
Hakim, F.T.8
Kochenderfer, J.N.9
-
32
-
-
0027178248
-
Potential clinical applications of signal transduction measurements in marrow transplantation and HIV-1 infection
-
June CH, Linette GP, Pierce PF, Jin NR and Lum LG. Potential clinical applications of signal transduction measurements in marrow transplantation and HIV-1 infection. Annals of the New York Academy of Sciences. 1993; 677:225-232.
-
(1993)
Annals of the New York Academy of Sciences
, vol.677
, pp. 225-232
-
-
June, C.H.1
Linette, G.P.2
Pierce, P.F.3
Jin, N.R.4
Lum, L.G.5
|